ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, mutated 177Y fail to develop CML and increase sensitivity to imatinib, suggesting a target of Y177 to eliminate the leukemic stem cells.17 Rho/GEF retained in p230 and p210 BCR-ABL but not in p190, thought to facilitate calcium-dependent lipid binding, restrict proliferation and support survival.18